Anthem · Semaglutide · US health-plan appeal rights

Semaglutide denied as non-formulary by Anthem?

Q: How long do I have to appeal a Anthem Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem semaglutide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Semaglutide

## Anthem Non-Formulary Denials for Semaglutide: The Tiering Mechanics That Drive Reversal

Anthem's "non-formulary" denial on semaglutide (Ozempic/Wegovy/Rybelsus) is rarely a true exclusion — it is almost always a tier placement decision under Anthem's commercial National Drug List (Essential, Select, or National), administered through CarelonRx (Anthem's in-house PBM, which replaced IngenioRx effective 2023). The denial mechanic matters: a Tier-NF letter triggers the formulary-exception pathway under 29 CFR §2560.503-1, not the medical-necessity appeal pathway. Confusing the two is the most common reason these appeals fail on procedure rather than substance.

### Anchor the Exception Request to the Correct Anthem Policy

For semaglutide indicated for T2DM, the operative Anthem clinical criteria document is CG-DRUG-110 (GLP-1 Receptor Agonists) and the companion Pharmacy Coverage Guideline for Semaglutide Products. Both require documentation of (a) T2DM diagnosis confirmed by ICD-10 E11.x, and (b) HbA1c ≥6.5% within the prior 12 months — exactly the coverage criteria triggering this denial pathway. When the patient meets these clinical thresholds but the drug is non-formulary, the appeal is not asking Anthem to override its medical policy; it is asking Anthem to grant a formulary exception because preferred alternatives (typically Trulicity/dulaglutide on Anthem's Select formulary, or Mounjaro on certain 2025 lists) are clinically inappropriate, contraindicated, or have been tried and failed.

### The Federal Lever: Step-Therapy Override Rights

Under 29 USC §1185d and ACA §2706, Anthem must grant an exception within 72 hours (24 hours expedited) when the prescriber attests the formulary alternative will (i) be ineffective, (ii) cause an adverse reaction, (iii) not be in the patient's best interest, or (iv) the patient is already stable on semaglutide. Anthem's CarelonRx exception form (available via the provider portal or fax 1-844-490-4877) maps directly to these statutory grounds — the prescriber statement must mirror the statutory language verbatim, not paraphrase it. ERISA disclosure rules under 29 CFR §2560.503-1(g) entitle the member to the specific formulary tiering rationale and the comparative clinical evidence Anthem relied on; demand it in writing.

### Tactical Closer

If CarelonRx denies the exception, escalate simultaneously on two tracks: (1) external IRO review under the ACA (request within 4 months — Anthem uses MAXIMUS or MCMC depending on state), and (2) a parallel state DOI complaint. In fully-insured Anthem states (CA, CO, CT, GA, IN, KY, ME, MO, NH, NV, NY, OH, VA, WI), the DOI complaint frequently produces a reversal faster than IRO review because Anthem's regulatory affairs team triages DOI files within 5 business days. Cite Pinto v. Aetna Life Ins. Co. on Anthem's burden to articulate a reasoned basis tied to the administrative record — boilerplate "non-formulary" language without a comparative-evidence rationale is reversible as arbitrary and capricious.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Semaglutide

Other denial reasons for Anthem Semaglutide

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.